On June 4, 2026, a symposium dedicated to liquid biopsy in oncology was held in Paris, bringing together numerous French and international experts around the challenges of implementation in clinical practice. The discussions focused on the growing use of these technologies in the management of metastatic cancers, as well as in perioperative settings. RespirERA Institute, represented by Pr Paul Hofman, spoke on the perspectives of liquid biopsy in the early detection of lung cancers.
A national meeting dedicated to the implementation of liquid biopsy
Organized by the Gustave Roussy Institute, this symposium on June 4, 2026, brought together in Paris specialists in oncology, molecular biology, and pathology to review recent advances and challenges related to the integration of liquid biopsy into care pathways.
In a context where diagnostic innovations are progressing rapidly, the exchanges highlighted a central challenge: transforming innovative biological tools into accessible and standardized clinical practices throughout the country.
An increasing role in cancer management
The discussions highlighted the increasingly important role of liquid biopsy in the management of cancer patients, particularly in metastatic situations, where molecular monitoring allows for more finely tuned therapeutic strategies.
Liquid biopsy, based on the analysis of tumor fragments circulating in the blood, also offers perspectives in perioperative settings, notably to refine the assessment of recurrence risk and post-treatment monitoring.
These advances illustrate the progressive evolution toward a more personalized oncology, relying on biological data that is dynamic and repeatable over time.
RespirERA Institute mobilized on the early detection of lung cancers
In this context, Pr Paul Hofman, director of RespirERA Institute, spoke to present the perspectives of liquid biopsy in the early detection of lung cancers.
This approach, still in development, aims to identify early biological signals associated with the presence of cancer, in order to improve the chances of diagnosis at an initial stage of the disease, where therapeutic options are most effective.
The intervention made it possible to place respiratory health and lung cancer back at the heart of current precision medicine challenges.
Experts gathered around the challenges of precision medicine
The symposium brought together several major figures in oncology research and clinical practice, including Pr Étienne Rouleau, Pr Antoine Italiano, Pr Catherine Alix-Panabières, and Pr Paul Hofman.
Their interventions provided an opportunity to address the challenges of structuring care pathways, the clinical validation of liquid biopsy tools, and the harmonization of practices among expert centers.
FR 
EN 